Efficacy of HER2-Based Therapy in Patients After Failure of Prior T-DM1 Therapy and the Evaluation of an Anti-HER2 Combination Regimen


Efficacy of HER2-Based Therapy in Patients After Failure of Prior T-DM1 Therapy and the Evaluation of an Anti-HER2 Combination Regimen
Slides from presentations at SABCS 2010 and comments from a recent interview with William J Gradishar, MD (1/4/11)

Diéras V et al. A phase Ib/II trial of trastuzumab-DM1 with pertuzumab for patients with HER2-positive, locally advanced or metastatic breast cancer: Interim efficacy and safety results. San Antonio Breast Cancer Symposium 2010;Abstract P3-14-01.

Olson EM et al. Responses to subsequent anti-HER2 therapy after treatment with trastuzumab-DM1 in women with HER2-positive metastatic breast cancer. San Antonio Breast Cancer Symposium 2010;Abstract P3-14-08.

Dr Gradishar is Director of Breast Medical Oncology at the Robert H Lurie Comprehensive Cancer Center and Professor of Medicine at the Northwestern University Feinberg School of Medicine in Chicago, Illinois.